Home > Cardiology > ACC 2021 > Electrophysiology > Finerenone reduces the risk of AF onset in patients with CKD and diabetes

Finerenone reduces the risk of AF onset in patients with CKD and diabetes

Presented By
Prof. Gerasimos Filippatos, Attikon University Hospital, Greece
Conference
ACC 2021
Trial
Phase 3, FIDELIO-DKD
An analysis of the FIDELIO-DKD trial demonstrated that finerenone decreased new-onset atrial fibrillation or flutter (AFF) in patients who have type 2 diabetes (T2D) and chronic kidney disease (CKD) irrespective of AFF history at baseline [1,2]. T2D and CKD are both promoters of AFF via structural and/or electrical remodelling, which is triggered by activation of mineralocorticoid receptors. Finerenone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist with anti-inflammatory and anti-fibrotic effects. Prof. Gerasimos Filippatos (Attikon University Hospital, Greece) presented a prespecified analysis of the FIDELIO-DKD trial (NCT02540993) [1]. The analysis examined the cardiorenal effects and impact of finerenone on new-onset AFF in participants with T2D and CKD. The multicentre, double-blinded, ph...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on